CORAL GABLES, Fla., June 13, 2016 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) on a confirmatory Phase 3 study protocol for Firdapse® (amifampridine phosphate) for the symptomatic treatment of Lambert-Eaton myasthenic syndrome (LEMS). As part of the clinical protocol for the confirmatory study, Catalyst expects to initiate a small, single-center study with Firdapse during the second half of 2016. Catalyst also expects to announce additional information about the study design and timelines for the study once they are finalized.

Click here to read the full release

Leave a comment

CORAL GABLES, Fla., June 01, 2016 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced that the Company will be presenting at the Jefferies 2016 Healthcare Conference, in New York.  Patrick J. McEnany, Catalyst’s Chief Executive Officer and Steven Miller, Ph.D., Chief Scientific Officer/COO, will provide an overview of the Company and its key programs on Tuesday, June 7 at 4:30 pm ET.  The Company’s presentation materials will be available on the “Investors” section of the Company’s website, www.catalystpharma.com following the presentation.

Click here to read the full text: http://ir.catalystpharma.com/releasedetail.cfm?ReleaseID=973677

Leave a comment

CORAL GABLES, Fla., May 18, 2016 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today reported on the publication of detailed results from the LMS-002 Phase 3 study of amifampridine phosphate (Firdapse®) in patients with Lambert-Eaton myasthenic syndrome (LEMS). The study results were published in the May 2016 issue of Muscle & Nerve (volume 53, number 5), authored by Dr. Shin Oh, et al.

Click here to read the full text: http://ir.catalystpharma.com/releasedetail.cfm?ReleaseID=971530

Leave a comment

CORAL GABLES, Fla., May 17, 2016 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced that the company is reducing its workforce by approximately 30%. The reduction in workforce, which affects employees from Catalyst’s commercial team, is part of Catalyst’s ongoing efforts to conserve cash as it works to complete the requirements for an NDA submission of Firdapse® (amifampridine phosphate) for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) and congenital myasthenic syndromes (CMS).

Click here to read the full text: http://ir.catalystpharma.com/releasedetail.cfm?ReleaseID=969680

Leave a comment

CORAL GABLES, Fla., May 10, 2016 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today reported financial results for the first quarter ended March 31, 2016.

Click here to read the full text: http://ir.catalystpharma.com/releasedetail.cfm?ReleaseID=970378

Leave a comment

CORAL GABLES, Fla., May 06, 2016 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced that it will release First Quarter 2016 financial results after market close on Tuesday, May 10, 2016. Further, Catalyst management will host an investment-community conference call at 8:30 a.m. EDT on Wednesday, May 11, 2016 to discuss the financial results and to provide a corporate update.

Click here to read the full text: http://ir.catalystpharma.com/releasedetail.cfm?ReleaseID=969680

Leave a comment

CORAL GABLES, Fla., April 26, 2016 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today provided an update on the content of the planned resubmission of the New Drug Application (“NDA”) for Firdapse® (amifampridine phosphate), which currently has Breakthrough Therapy and Orphan Drug designations for Lambert-Eaton myasthenic syndrome (LEMS). Catalyst recently met with the Food and Drug Administration (“FDA”) to obtain greater clarity regarding what will be required by the FDA to accept the Firdapse NDA for filing.

Click here to read the full text: http://ir.catalystpharma.com/releasedetail.cfm?ReleaseID=966761

Leave a comment

CORAL GABLES, Fla., March 15, 2016 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today reported financial results for the fourth quarter and the year-ended December 31, 2015.

Click here to read the full text: http://ir.catalystpharma.com/releasedetail.cfm?ReleaseID=960789

Leave a comment

CORAL GABLES, Fla., March 10, 2016 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced that the Company will be presenting at the 28th Annual ROTH Conference in California. Steven Miller, Ph.D., Chief Scientific Officer/COO, will provide an overview of the Company and its key programs on Tuesday, March 15th at 9:00 am PT / 12:00 pm ET.  The Company’s presentation materials will be available on the “Investors” section of the Company’s website, www.catalystpharma.com following the presentation.

Click here to read the full text: http://ir.catalystpharma.com/releasedetail.cfm?ReleaseID=959964

Leave a comment

CORAL GABLES, Fla., March 09, 2016 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced that it will release Fourth Quarter and Year-End 2015 financial results after market close on Tuesday, March 15, 2016. Further, Catalyst management will host an investment-community conference call at 8:30 a.m. EDT on Wednesday March 16, 2016 to discuss the financial results and to provide a corporate update.

Click here to read the full text: http://ir.catalystpharma.com/releasedetail.cfm?ReleaseID=959629

Leave a comment
Follow

Get every new post delivered to your Inbox.

Join 304 other followers

%d bloggers like this: